Blood–brain barrier dysfunction in immuno-mediated neurological diseases

References

• Abbott NJ, Rönnbäck L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 2006;7:41–53.
   PubMed Web of Science ®Google Scholar
• Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008;57:178–201.
   PubMed Web of Science ®Google Scholar
• Obermeier B, Daneman R, Ransohoff RM. Development, maintenance and disruption of the blood-brain barrier. Nat Med. 2013;19:1584–1596.
   PubMed Web of Science ®Google Scholar
• Man S, Ubogu EE, Ransohoff RM. Inflammatory cell migration into the central nervous system: a few new twists on an old tale. Brain Pathol. 2007;17:243–250.
   Web of Science ®Google Scholar
• Kniesel U, Wolburg H. Tight junctions of the blood-brain barrier. Cell Mol Neurobiol. 2000;20:57–76.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Nelson AR, Betsholtz C, et al. Establishment and dysfunction of the blood-brain barrier. Cell. 2015;163:1064–1078.
   PubMed Web of Science ®Google Scholar
• Winkler EA, Bell RD, Zlokovic BV. Central nervous system pericytes in health and disease. Nat Neurosci. 2011;14:1398–1405.
   PubMed Web of Science ®Google Scholar
• Sweeney MD, Sagare AP, Zlokovic BV. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol. 2018;14:133–150.
   PubMed Web of Science ®Google Scholar
• Takeshita Y, Ransohoff RM. Inflammatory cell trafficking across the blood-brain barrier: chemokine regulation and in vitro models. Immunol Rev. 2012;248:228–239.
   Web of Science ®Google Scholar
• Bernas MJ, Cardoso FL, Daley SK, et al. Establishment of primary cultures of human brain microvascular endothelial cells to provide an in vitro cellular model of the blood-brain barrier. Nat Protoc. 2010;5:1265–1272.
   PubMed Web of Science ®Google Scholar
• Nakagawa S, Deli MA, Kawaguchi H, et al. A new blood-brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes. Neurochem Int. 2009;54:253–263.
   PubMed Web of Science ®Google Scholar
• Weksler BB, Subileau EA, Perrière N, et al. Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J. 2005;19:1872–1874.
   PubMed Web of Science ®Google Scholar
• Poller B, Gutmann H, Krähenbühl S, et al. The human brain endothelial cell line hCMEC/D3 as a human blood-brain barrier model for drug transport studies. J Neurochem. 2008;107:1358–1368.
   PubMed Web of Science ®Google Scholar
• Sano Y, Shimizu F, Abe M, et al. Establishment of a new conditionally immortalized human brain microvascular endothelial cell line retaining an in vivo blood-brain barrier function. J Cell Physiol. 2010;225:519–528.
   PubMed Web of Science ®Google Scholar
• Sano Y, Kashiwamura Y, Abe M, et al. Stable human brain microvascular endothelial cell line retaining its barrier-specific nature independent of the passage number. Clin Exp Neuroimmunol. 2013;4:92–103.
   Google Scholar
• Shimizu F, Sano Y, Maeda T, et al. Peripheral nerve pericytes originating from the blood-nerve barrier expresses tight junctional molecules and transporters as barrier-forming cells. J Cell Physiol. 2008;217:388–399.
   PubMed Web of Science ®Google Scholar
• Shimizu F, Sano Y, Abe M, et al. Peripheralnerve pericytes modify the blood-nerve barrier function and tight junctional molecules through the secretion of various soluble factors. J Cell Physiol. 2011;226:255–266.
   PubMed Web of Science ®Google Scholar
• Waubant E. Biomarkers indicative of blood-brain barrier disruption in multiple sclerosis. Dis Markers. 2006;22:235–244.
   PubMed Web of Science ®Google Scholar
• Lefvert AK, Link H. IgG production within the central nervous system: a critical review of proposed formulae. Ann Neurol. 1985;17:13–20.
   PubMed Web of Science ®Google Scholar
• Wolburg H, Lippoldt A. Tight junctions of the blood-brain barrier: development, composition and regulation. Vasc Pharmacol. 2002;38:323–337.
   PubMed Web of Science ®Google Scholar
• Nitta T, Hata M, Gotoh S. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J Cell Biol. 2003;161:653–660.
   PubMed Web of Science ®Google Scholar
• Engelhardt B. T cell migration into the central nervous system during health and disease: different molecular keys allow access to different central nervous system compartments. Clin Exp Neuroimmunol. 2010;1:79–93.
   Google Scholar
• Shimizu F, Kanda T. The blood-brain barrier in neuroinflammation. In: Suzumura A, Ikenaka K, editors. Neuron-glia interaction in neuroinflammation. New York, NY: Springer Science + Business Media New York; 2013. p. 157–179.
   Google Scholar
• Alvarez JI, Saint-Laurent O, Godschalk A, et al. Focal disturbances in the blood-brain barrier are associated with formation of neuroinflammatory lesions. Neurobiol Dis. 2015;74:14–24.
   PubMed Web of Science ®Google Scholar
• Förster C, Burek M, Romero IA, et al. Differential effects of hydrocortisone and TNF alpha on tight junction proteins in an in vitro model of the human blood-brain barrier. J Physiol. 2008;586:1937–1949.
   Web of Science ®Google Scholar
• Nishihara H, Shimizu F, Sano Y, et al. Fingolimod prevents blood-brain barrier disruption induced by the sera from patients with multiple sclerosis. PLoS One. 2015;10:e0121488.
   PubMed Web of Science ®Google Scholar
• Takahashi S, Maeda T, Sano Y, et al. Active form of vitamin D directly protects the blood–brain barrier in multiple sclerosis. Clin Exp Neuroimmunol. 2017;8:244–254.
   Google Scholar
• Miller DH, Soon D, Fernando KT, et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology. 2007;68:1390–1401.
   PubMed Web of Science ®Google Scholar
• Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med. 2000;343:938–952.
   PubMed Web of Science ®Google Scholar
• Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;46:907–911.
   PubMed Web of Science ®Google Scholar
• Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015;14:183–193.
   PubMed Web of Science ®Google Scholar
• Ontaneda D, Fox RJ, Chataway J. Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. Lancet Neurol. 2015;14:208–223.
   PubMed Web of Science ®Google Scholar
• Dutta R, Trapp BD. Relapsing and progressive forms of multiple sclerosis: insights from pathology. Curr Opin Neurol. 2014;27:271–278.
   PubMed Web of Science ®Google Scholar
• Leray E, Yaouanq J, Le Page E, et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain. 2010;133:1900–1913.
   PubMed Web of Science ®Google Scholar
• Oh J, O’Connor PW. Established disease-modifying treatments in relapsing-remitting multiple sclerosis. Curr Opin Neurol. 2015;28:220–229.
   PubMed Web of Science ®Google Scholar
• Alvarez JI, Cayrol R, Prat A. Disruption of central nervous system barriers in multiple sclerosis. Biochim Biophys Acta. 2011;1812:252–264.
   Web of Science ®Google Scholar
• Larochelle C, Alvarez JI, Prat A. How do immune cells overcome the blood-brain barrier in multiple sclerosis? FEBS Lett. 2011;585:3770–3780.
   PubMed Web of Science ®Google Scholar
• Kirk J, Plumb J, Mirakhur M, et al. Tight junctional abnormality in multiple sclerosis white matter affects all calibres of vessel and is associated with blood-brain barrier leakage and active demyelination. J Pathol. 2003;201:319–327.
   PubMed Web of Science ®Google Scholar
• Plumb J, McQuaid S, Mirakhur M, et al. Abnormal endothelial tight junctions in active lesions and normal-appearing white matter in multiple sclerosis. Brain Pathol. 2006;12:154–169.
   Google Scholar
• Leech S, Kirk J, Plumb J, et al. Persistent endothelial abnormalities and blood-brain barrier leak in primary and secondary progressive multiple sclerosis. Neuropathol Appl Neurobiol. 2007;33:86–98.
   PubMed Web of Science ®Google Scholar
• Shimizu F, Tasaki A, Sano Y, et al. Sera from remitting and secondary progressive multiple sclerosis patients disrupt the blood-brain barrier. PLoS One. 2014;9:e92872.
   Web of Science ®Google Scholar
• Nishihara H, Shimizu F, Kitagawa T, et al. Identification of galectin-3 as a possible antibody target for secondary progressive multiple sclerosis. Mult Scler. 2017;23:382–394.
   Google Scholar
• Li LC, Li J, Gao J. Functions of galectin-3 and its role in fibrotic diseases. J Pharmacol Exp Ther. 2014;351:336–343.
   PubMed Web of Science ®Google Scholar
• Dumic J, Dabelic S, Flögel M. Galectin-3: an open-ended story. Biochim Biophys Acta. 2006;1760:616–635.
   PubMed Web of Science ®Google Scholar
• Radosavljevic G, Volarevic V, Jovanovic I, et al. The roles of galectin-3 in autoimmunity and tumor progression. Immunol Res. 2012;52:100–110.
   PubMed Web of Science ®Google Scholar
• Jeon SB, Yoon HJ, Chang CY, et al. Galectin-3 exerts cytokine-like regulatory actions through the JAK-STAT pathway. J Immunol. 2010;185:7037–7046.
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Rosenthal H, Cymring B, et al. Progressive multiple sclerosis cerebrospinal fluid induces inflammatory demyelination, axonal loss, and astrogliosis in mice. Exp Neurol. 2014;261:620–632.
   PubMed Web of Science ®Google Scholar
• Shi ZR, Tan GZ, Meng Z, et al. Association of anti-acidic ribosomal protein P0 and anti-galectin 3 antibodies with the development of skin lesions in systemic lupus erythematosus. Arthritis Rheumatol. 2015;67:193–203.
   Web of Science ®Google Scholar
• Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66:1485–1489.
   PubMed Web of Science ®Google Scholar
• Yanagawa K, Kawachi I, Toyoshima Y, et al. Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis. Neurology. 2009;73:1628–1637.
   PubMed Web of Science ®Google Scholar
• Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202:473–477.
   PubMed Web of Science ®Google Scholar
• Hinson SR, Romero MF, Popescu BF, et al. Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci USA. 2012;109:1245–1250.
   PubMed Web of Science ®Google Scholar
• Waters P, Reindl M, Saiz A, et al. Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2016;87:1005–1015.
   PubMed Web of Science ®Google Scholar
• Kim SM, Waters P, Vincent A, et al. Cerebrospinal fluid/serum gradient of IgG is associated with disability at acute attacks of neuromyelitis optica. J Neurol. 2011;258:2176–2180.
   Web of Science ®Google Scholar
• Jarius S, Franciotta D, Paul F, et al. Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance. J Neuroinflammation. 2010;7:52.
   PubMed Web of Science ®Google Scholar
• Kowarik MC, Dzieciatkowska M, Wemlinger S, et al. The cerebrospinal fluid immunoglobulin transcriptome and proteome in neuromyelitis optica reveals central nervous system-specific B cell populations. J Neuroinflammation. 2015;12:19.
   Web of Science ®Google Scholar
• Bradl M, Misu T, Takahashi T, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol. 2009;66:630–643.
   PubMed Web of Science ®Google Scholar
• Sharma R, Fischer MT, Bauer J, et al. Inflammation induced by innate immunity in the central nervous system leads to primary astrocyte dysfunction followed by demyelination. Acta Neuropathol. 2010;120:223–236.
   PubMed Web of Science ®Google Scholar
• Shimizu F, Sano Y, Takahashi T, et al. Sera from neuromyelitis optica patients disrupt the blood-brain barrier. J Neurol Neurosurg Psychiatry. 2012;83:288–297.
   PubMed Web of Science ®Google Scholar
• Tasaki A, Shimizu F, Sano Y, et al. Autocrine MMP-2/9 secretion increases the BBB permeability in neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2014;85:419–430.
   Web of Science ®Google Scholar
• Shimizu F, Nishihara H, Sano Y, et al. Markedly increased IP-10 production by blood-brain barrier in neuromyelitis optica. PLoS One. 2015;10:e0122000.
   Web of Science ®Google Scholar
• Shimizu F, Schaller KL, Owens GP, et al. Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica. Sci Transl Med. 2017;9. DOI:10.1126/scitranslmed.aai9111
   Web of Science ®Google Scholar
• Lee AS. Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential. Nat Rev Cancer. 2014;14:263–276.
   PubMed Web of Science ®Google Scholar
• Misra UK, Deedwania R, Pizzo SV. Activation and cross-talk between Akt, NF-kappaB, and unfolded protein response signaling in 1-LN prostate cancer cells consequent to ligation of cell surface-associated GRP78. J Biol Chem. 2006;281:13694–13707.
   PubMed Web of Science ®Google Scholar
• Luo B, Lee AS. The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies. Oncogene. 2013;32:805–818.
   PubMed Web of Science ®Google Scholar
• Raiter A, Vilkin A, Gingold R, et al. The presence of anti-GRP78 antibodies in the serum of patients with colorectal carcinoma: a potential biomarker for early cancer detection. Int J Biol Markers. 2014;29:e431.
   PubMed Web of Science ®Google Scholar
• Bläss S, Union A, Raymackers J, et al. The stress protein BiP is overexpressed and is a major B and T cell target in rheumatoid arthritis. Arthritis Rheum. 2001;44:761–771.
   PubMed Web of Science ®Google Scholar
• Jeltsch-David H, Muller S. Neuropsychiatric systemic lupus erythematosus: pathogenesis and biomarkers. Nat Rev Neurol. 2014;10:579–596.
   PubMed Web of Science ®Google Scholar
• Sciascia S, Bertolaccini ML, Baldovino S, et al. Central nervous system involvement in systemic lupus erythematosus: overview on classification criteria. Autoimmun Rev. 2013;12:426–429.
   Web of Science ®Google Scholar
• Stock AD, Wen J, Putterman C. Neuropsychiatric lupus, the blood brain barrier, and the TWEAK/Fn14 pathway. Front Immunol. 2013;4:484.
   PubMed Web of Science ®Google Scholar
• Bertsias GK, Boumpas DT. Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations. Nat Rev Rheumatol. 2010;6:358–367.
   PubMed Web of Science ®Google Scholar
• Brimberg L, Mader S, Fujieda Y, et al. Antibodies as mediators of brain pathology. Trends Immunol. 2015;36:709–724.
   PubMed Web of Science ®Google Scholar
• Mader S, Brimberg L, Diamond B. The role of brain-reactive autoantibodies in brain pathology and cognitive impairment. Front Immunol. 2017;8:1101.
   PubMed Web of Science ®Google Scholar
• Kowal C, Degiorgio LA, Lee JY, et al. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc Natl Acad Sci USA. 2006;103:19854–19859.
   PubMed Web of Science ®Google Scholar
• Kowal C, DeGiorgio LA, Nakaoka T, et al. Cognition and immunity; antibody impairs memory. Immunity. 2004;21:179–188.
   PubMed Web of Science ®Google Scholar
• McLean BN, Miller D, Thompson EJ. Oligoclonal banding of IgG in CSF, blood-brain barrier function, and MRI findings in patients with sarcoidosis, systemic lupus erythematosus, and Behçet's disease involving the nervous system. J Neurol Neurosurg Psychiatry. 1995;58:548–554.
   Web of Science ®Google Scholar
• Hirohata S, Arinuma Y, Yanagida T, et al. Blood-brain barrier damages and intrathecal synthesis of anti-N-methyl-D-aspartate receptor NR2 antibodies in diffuse psychiatric/neuropsychological syndromes in systemic lupus erythematosus. Arthritis Res Ther. 2014;16:R77.
   PubMed Web of Science ®Google Scholar
• Conti F, Alessandri C, Bompane D, et al. Autoantibody profile in systemic lupus erythematosus with psychiatric manifestations: a role for anti-endothelial-cell antibodies. Arthritis Res Ther. 2004;6:R366–R372.
   Web of Science ®Google Scholar
• Carvalho D, Savage CO, Isenberg D, et al. IgG anti-endothelial cell autoantibodies from patients with systemic lupus erythematosus or systemic vasculitis stimulate the release of two endothelial cell-derived mediators, which enhance adhesion molecule expression and leukocyte adhesion in an autocrine manner. Arthritis Rheum. 1999;42:631–640.
   PubMed Web of Science ®Google Scholar
• Renaudineau Y, Dugué C, Dueymes M, et al. Antiendothelial cell antibodies in systemic lupus erythematosus. Autoimmun Rev. 2002;1:365–372.
   PubMedGoogle Scholar
• Kalra S, Silman A, Akman-Demir G, et al. Diagnosis and management of Neuro-Behçet's disease: international consensus recommendations. J Neurol. 2014;261:1662–1676.
   PubMed Web of Science ®Google Scholar
• Hirohata S. Histopathology of central nervous system lesions in Behçet's disease. J Neurol Sci. 2008;267:41–47.
   PubMed Web of Science ®Google Scholar
• Hirohata S, Kikuchi H, Sawada T, et al. Clinical characteristics of neuro-Behcet's disease in Japan: a multicenter retrospective analysis. Mod Rheumatol. 2012;22:405–413.
   PubMed Web of Science ®Google Scholar
• Ishido M, Horita N, Takeuchi M, et al. Distinct clinical features between acute and chronic progressive parenchymal neuro-Behçet disease: meta-analysis. Sci Rep. 2017;7:10196.
   Web of Science ®Google Scholar
• Kikuchi H, Takayama M, Hirohata S. Quantitative analysis of brainstem atrophy on magnetic resonance imaging in chronic progressive neuro-Behçet's disease. J Neurol Sci. 2014;337:80–85.
   Web of Science ®Google Scholar
• Hirohata S, Kikuchi H, Sawada T, et al. Retrospective analysis of long-term outcome of chronic progressive neurological manifestations in Behcet's disease. J Neurol Sci. 2015;349:143–148.
   PubMed Web of Science ®Google Scholar